Bromazolam is a triazolobenzodiazepine (TBZD) derivative which was first synthesized in 1976, & never marketed. It is the bromo analogue of alprazolam and has a similar sedative-hypnotic and anxiolytic side effect profile.
Bromazolam is a non-subtype selective agonist at the benzodiazepine site complex of GABA-A receptors, with a strong binding affinity. The “common” dosage for users of Bromazolam has been reported to be 3-4mg, respectively suggesting its potency is slightly weaker than that of alprazolam.
Reviews
There are no reviews yet.